A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Trial Profile

A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 15 Aug 2017 According to an Onconova Therapeutics media release, the Company is taking proactive measures to increase enrollment including the addition of trial sites in three new countries and changes within its CRO group and full enrollment may be delayed by several months if not reached desired level.
    • 15 Aug 2017 According to an Onconova Therapeutics media release, an interim analysis for this study is anticipated in the fourth quarter.
    • 27 May 2017 Pre-planned interim analysis for this trial is currently on track and will be conducted after 88 death events have occurred, according to an Onconova Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top